Geneva, July 20 -- International Clinical Trials Registry received information related to the study (KCT0012253) titled 'A PROSPECTIVE PHASE 2 STUDY OF THE COMBINATION OF POLATUZUMAB VEDOTIN AND GLOFITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA WITHIN 12 MONTHS OF R-CHOP TREATMENT' on July 8.
Study Type: Interventional Study
Study Design:
Primary Purpose : Treatment, Intervention Model : Single Group, Blinding/Masking : Open, Allocation : Not Applicable
Primary Sponsor: Yonsei University Health System, Severance Hospital
Condition:
Neoplasms
Intervention:
Drug : Subjects who meet all inclusion and exclusion criteria and provide informed consent will start study treatment. This is a single-arm, open-...